Editorial: Phenotypes of myasthenia gravis, volume II

doi:10.3389/fneur.2023.1335308

Editorial

. 2023 Nov 24:14:1335308.

doi: 10.3389/fneur.2023.1335308. eCollection 2023.

Editorial: Phenotypes of myasthenia gravis, volume II

Hai-Feng Li¹, Nils Erik Gilhus^{2

3}, Qun Xue⁴, Feng Gao⁵

Affiliations

¹ Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
² Department of Neurology, Haukeland University Hospital, Bergen, Norway.
³ Department of Clinical Medicine, University of Bergen, Bergen, Norway.
⁴ Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China.
⁵ Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.

PMID: 38073651
PMCID: PMC10704596
DOI: 10.3389/fneur.2023.1335308

Editorial

Editorial: Phenotypes of myasthenia gravis, volume II

Hai-Feng Li et al. Front Neurol. 2023.

. 2023 Nov 24:14:1335308.

doi: 10.3389/fneur.2023.1335308. eCollection 2023.

Authors

Hai-Feng Li¹, Nils Erik Gilhus^{2

3}, Qun Xue⁴, Feng Gao⁵

Affiliations

¹ Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
² Department of Neurology, Haukeland University Hospital, Bergen, Norway.
³ Department of Clinical Medicine, University of Bergen, Bergen, Norway.
⁴ Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China.
⁵ Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.

PMID: 38073651
PMCID: PMC10704596
DOI: 10.3389/fneur.2023.1335308

No abstract available

Keywords: assessment; biomarker; myasthenia gravis; phenotype; roadmap.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

Editorial on the Research Topic Phenotypes of myasthenia gravis, volume II

References

1. Li T, Yang C-L, Du T, Zhang P, Zhou Y, Li X-L, et al. . Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells. Clin Immunol. (2022) 245:109141. 10.1016/j.clim.2022.109141 - DOI - PubMed
1. Jiang P, Li J, Li H-Y, Zhang B, Yue Y-X, Wang S-Y, et al. . Minimal manifestation status indicates a stable state in myasthenia gravis: a quantitative study. Front Neurol. (2022) 13:880045. 10.3389/fneur.2022.880045 - DOI - PMC - PubMed
1. Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Jr JFH, et al. . Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. (2017) 89:1069–77. 10.1212/WNL.0000000000004341 - DOI - PubMed
1. Chen X, Li HF. A narrative review of identifying the culprit antibody in neuroimmune diseases: concept and clinical significance. Ann Transl Med. (2023) 11:279. 10.21037/atm-21-1627 - DOI - PMC - PubMed
1. Michail M, Zouvelou V, Belimezi M, Haroniti A, Zouridakis M, Zisimopoulou P. Analysis of nAChR autoantibodies against extracellular epitopes in MG patients. Front Neurol. (2022) 13:858998. 10.3389/fneur.2022.858998 - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Li T, Yang C-L, Du T, Zhang P, Zhou Y, Li X-L, et al. . Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells. Clin Immunol. (2022) 245:109141. 10.1016/j.clim.2022.109141 - DOI - PubMed

[2] Li T, Yang C-L, Du T, Zhang P, Zhou Y, Li X-L, et al. . Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells. Clin Immunol. (2022) 245:109141. 10.1016/j.clim.2022.109141 - DOI - PubMed

[3] Jiang P, Li J, Li H-Y, Zhang B, Yue Y-X, Wang S-Y, et al. . Minimal manifestation status indicates a stable state in myasthenia gravis: a quantitative study. Front Neurol. (2022) 13:880045. 10.3389/fneur.2022.880045 - DOI - PMC - PubMed

[4] Jiang P, Li J, Li H-Y, Zhang B, Yue Y-X, Wang S-Y, et al. . Minimal manifestation status indicates a stable state in myasthenia gravis: a quantitative study. Front Neurol. (2022) 13:880045. 10.3389/fneur.2022.880045 - DOI - PMC - PubMed

[5] Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Jr JFH, et al. . Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. (2017) 89:1069–77. 10.1212/WNL.0000000000004341 - DOI - PubMed

[6] Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Jr JFH, et al. . Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. (2017) 89:1069–77. 10.1212/WNL.0000000000004341 - DOI - PubMed

[7] Chen X, Li HF. A narrative review of identifying the culprit antibody in neuroimmune diseases: concept and clinical significance. Ann Transl Med. (2023) 11:279. 10.21037/atm-21-1627 - DOI - PMC - PubMed

[8] Chen X, Li HF. A narrative review of identifying the culprit antibody in neuroimmune diseases: concept and clinical significance. Ann Transl Med. (2023) 11:279. 10.21037/atm-21-1627 - DOI - PMC - PubMed

[9] Michail M, Zouvelou V, Belimezi M, Haroniti A, Zouridakis M, Zisimopoulou P. Analysis of nAChR autoantibodies against extracellular epitopes in MG patients. Front Neurol. (2022) 13:858998. 10.3389/fneur.2022.858998 - DOI - PMC - PubMed

[10] Michail M, Zouvelou V, Belimezi M, Haroniti A, Zouridakis M, Zisimopoulou P. Analysis of nAChR autoantibodies against extracellular epitopes in MG patients. Front Neurol. (2022) 13:858998. 10.3389/fneur.2022.858998 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Editorial: Phenotypes of myasthenia gravis, volume II

Affiliations

Editorial: Phenotypes of myasthenia gravis, volume II

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources